{"ticker": {"uuid": "784adee5-44cf-4806-8113-6f923f185502", "symbol": "TLSA", "name": "Tiziana Life Sciences Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcG9JN1ktLWpfZnRXRTVLWUJMYWFXb21pdDZsdHlHcFhyTl9IS1BVcjZVQnN2Wm80NmhzbE9GaHlFckRiWU5yN2YzYlB4MEVpTDh2Y0NzSmFXai01U3VINkhRYlpkVHNycjFJeUhScWk3aVJXUjNYUFJVbjVzei1OMW5MXzl6VnlPb3hHZGtEcHZVcTFXX20xbUl4LTJoWHIzYVRLcFFlZzR4NkFMRnZvY2cxdEY3RkhRd2RvLWpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T11:00:33+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This page from TradingView displays the \"Price to book forward\" metric for Tiziana Life Sciences Ltd (NASDAQ: TLSA). The content is primarily a data placeholder, indicating the financial metric for the company, and is surrounded by standard website navigation and footers. The act", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T19:40:23", "published_display": "07 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This article provides financial information for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its price to sales forward metric. It lists the company's stock exchange as Nasdaq and indicates that the market is currently closed with no trades. The content brie", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:12:12", "published_display": "07 Jul 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "The article discusses the enterprise value to revenue forward for Tiziana Life Sciences Ltd, traded on NASDAQ under the ticker TLSA. It presents financial information for the company, accessible through TradingView. The content provides a snapshot of the company's market and fina", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:40:33", "published_display": "05 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This article provides financial data for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its enterprise value to EBIT forward. The content appears to be a stub or an incomplete data presentation page from TradingView, lacking detailed analysis or narrative. It ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:39:25", "published_display": "05 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (DUS:0RP)", "summary": "This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (DUS:0RP), covering income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings report dates, net income figures, dividend policy, and employee ", "url": "https://www.tradingview.com/symbols/DUS-0RP/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T12:09:15", "published_display": "27 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (NASDAQ:TLSA)", "summary": "This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (NASDAQ:TLSA), including its current stock price, historical performance, analyst forecasts, and company financials. It also answers frequently asked questions regarding its stock ticker, market ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:45", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (LSX:A3C5SS)", "summary": "This article provides an overview of Tiziana Life Sciences Ltd. (A3C5SS) stock performance, financial actuals, and analyst estimates. It highlights the current stock price, recent declines, market capitalization, and upcoming earnings report. The piece also includes frequently as", "url": "https://www.tradingview.com/symbols/LSX-A3C5SS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:37", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment", "summary": "Tiziana Life Sciences has completed dosing the last patient in its Phase 2 clinical trial for its potential multiple sclerosis treatment, milciclib. The study aims to evaluate milciclib's efficacy and safety in patients with progressive multiple sclerosis. This milestone marks a ", "url": "https://www.moomoo.com/news/post/72034426/tiziana-life-sciences-doses-last-patient-in-phase-2-trial", "source_name": "Moomoo", "published_at": "2026-06-26T07:10:15", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Tiziana Life Sciences Ltd (TLSA) stock. According to one analyst, the 1-year price target is $9.01, with both the maximum and minimum estimates at this value. The article also covers current stock performance, historical highs", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:47", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial", "summary": "Tiziana Life Sciences has dosed the last patient in its Phase 2a clinical trial for intranasal foralumab to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study is anticipated in late Q3 or early Q4 2026, with results planned for presen", "url": "https://ca.finance.yahoo.com/news/tiziana-life-sciences-doses-last-130500188.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-25T17:09:16", "published_display": "25 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tiziana-announces-last-patient-successfully-110000190.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:00:00+00:00", "published_display": "25 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd.", "summary": "Tiziana Life Sciences has announced the successful dosing of the last patient in its Phase 2a INFORM-MS clinical trial for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study, which evaluates intranasal foralumab, a fully human anti-CD3 mono", "url": "https://via.ritzau.dk/pressemeddelelse/15013524/tiziana-life-sciences-ltd?publisherId=90446", "source_name": "Via Ritzau", "published_at": "2026-06-25T11:10:56", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana doses final INFORM-MS patient ahead of late-2026 data", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) has announced the successful dosing of the last patient in its Phase 2a INFORM-MS trial for intranasal foralumab, a treatment for non-active secondary progressive multiple sclerosis. Topline data from this randomized, double-blind, placebo-con", "url": "https://www.stocktitan.net/news/TLSA/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-ge3gmxouug4f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T11:10:56", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) has announced the completion of enrollment for its Phase 2a INFORM-MS trial, with the last patient dosed with intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This randomized, double-blind, placebo-contro", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-1125dc3b129c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T11:10:55", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tiziana Life Sciences Ltd (TLSA), detailing analyst ratings and target prices. Based on one analyst, the stock has a \"Buy\" rating with a target price of USD 8.00, representing a significant upside. The report highlights current marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:10", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tiziana Life Sciences Ltd (TLSA), focusing on its stock performance, indicators, and moving averages. It highlights that critical support and resistance data have not yet been disclosed by the company. The analysis shows an overall 'S", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsa/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:10", "published_display": "18 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (TLSA) insider awarded 15,000 common shares", "summary": "Tiziana Life Sciences Ltd. director Gabriele M. Cerrone was indirectly awarded 15,000 shares of common stock on June 12, 2026, at $1.11 per share through Panetta Partners Limited. This transaction increases his indirect holdings to 44,772,230 shares. The Form 4 filing indicates a", "url": "https://www.stocktitan.net/sec-filings/TLSA/form-4-tiziana-life-sciences-ltd-insider-trading-activity-3f8821dd93b6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:41:04", "published_display": "17 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance", "summary": "Tiziana Life Sciences' Executive Chairman, Gabriele Cerrone, has increased his stake in the company by purchasing 15,000 common shares for $1.11 each, bringing his total holding to 34.89%. This move demonstrates insider confidence as the company advances its intranasal foralumab ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TLSA/pressreleases/2490064/tiziana-life-sciences-chair-boosts-stake-as-foralumab-trials-advance/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T02:10:10", "published_display": "17 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman", "summary": "Tiziana Life Sciences announced that its Executive Chairman and Founder, Gabriele Cerrone, through Panetta Partners Ltd, purchased an additional 15,000 common shares at $1.11 per share. This transaction increases his total holdings to 44,772,230 common shares, representing 34.89%", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman/2365478", "source_name": "The Manila Times", "published_at": "2026-06-15T13:10:10", "published_display": "15 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tiziana-life-sciences-executive-chairman-115515620.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:55:15+00:00", "published_display": "15 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase", "summary": "Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his stake by purchasing 15,000 common shares at $1.11 each, bringing his total holding to 34.89% of the company's issued share capital. The company is developing intranasal foralumab, a fu", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-3d7fd22dad8a.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:09:08", "published_display": "15 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy", "summary": "Tiziana Life Sciences Executive Chairman and founder Gabriele Cerrone increased his stake in the company by purchasing 15,000 common shares at $1.11 each. This transaction, made through Panetta Partners, brings his total holding to 44,772,230 shares, representing 34.89% of the co", "url": "https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-executive-z2vnojl4ymyf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:09:08", "published_display": "15 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana executive chairman increases stake", "summary": "Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his ownership stake in the company through Panetta Partners Ltd. Cerrone purchased 15,000 common shares at $1.11 each, bringing his total holdings to 44.77 million shares, which represents", "url": "https://www.proactiveinvestors.com.au/companies/news/1093905/tiziana-executive-chairman-increases-stake-1093905.html", "source_name": "Proactive financial news", "published_at": "2026-06-15T08:09:57", "published_display": "15 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (Nasdaq:TLSA) - Stock Analysis", "summary": "Tiziana Life Sciences (Nasdaq:TLSA) is a biotechnology company focused on developing therapies for neurodegenerative and lung diseases. The company's lead product candidate, Foralumab, an intranasal anti-CD3 monoclonal antibody, is currently undergoing clinical trials for non-act", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlsa/tiziana-life-sciences", "source_name": "Simply Wall Street", "published_at": "2026-05-31T18:39:14", "published_display": "31 May 2026 18:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York", "summary": "Tiziana Life Sciences announced it will present at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide updates on the company's clinical programs and strategic direction. The presentation will high", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-present-jefferies-110000374.html", "source_name": "Market source", "published_at": "2026-05-31T08:39:47", "published_display": "31 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSA - Tiziana Life Sciences Ltd Stock Price and Quote", "summary": "This page provides a comprehensive overview of Tiziana Life Sciences Ltd (TLSA) stock, including its latest trading data, financial metrics, and recent news. The company is a clinical-stage biotechnology firm focused on therapies for neurodegenerative and lung diseases, with a pi", "url": "https://finviz.com/stock?t=TLSA", "source_name": "Finviz", "published_at": "2026-05-30T18:40:32", "published_display": "30 May 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Tiziana to brief investors on clinical updates at Jefferies event", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) announced it will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide corporate and clinical updates, including advancements for their lead candidate, intranasal foralumab", "url": "https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-to-present-at-the-jefferies-global-healthcare-umf753kly5bh.html", "source_name": "Stock Titan", "published_at": "2026-05-28T11:08:54", "published_display": "28 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC Filing - Form 6-K", "summary": "Tiziana Life Sciences (NASDAQ: TLSA) announced it will present at the Jefferies Healthcare Conference in New York City on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide a corporate presentation highlighting recent clinical and corporate developments, particula", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-d8239f192510.html", "source_name": "Stock Titan", "published_at": "2026-05-28T11:08:54", "published_display": "28 May 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial", "summary": "Tiziana Life Sciences has fully enrolled its Phase 2a placebo-controlled clinical trial (INFORM-MS) evaluating intranasal foralumab for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from this novel anti-CD3 monoclonal antibody study is ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tiziana-fully-enrolls-phase-2-150000587.html", "source_name": "Market source", "published_at": "2026-05-22T22:39:57", "published_display": "22 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data \u2013 ICYMI", "summary": "", "url": "https://finance.yahoo.com/m/f9476a36-8271-3245-96bc-18de094f904d/tiziana-life-sciences.html", "source_name": "Proactive", "published_at": "2026-05-22T20:48:00+00:00", "published_display": "22 May 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial", "summary": "", "url": "https://finance.yahoo.com/m/c0f1401c-3ce0-34aa-ba3b-291b4f31034b/tiziana-life-sciences.html", "source_name": "Proactive", "published_at": "2026-05-21T15:44:00+00:00", "published_display": "21 May 2026 15:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPT2E4a05nemNrTHp6X05GMVJ6bzVLWktLTVprOXE0UDlSall3TktBbXdhYnlHaDNZVnlIRTRGSk1Mb1FIclpmSWxtaFlNcFJ5TGNTeG9ZWUdvSEtmRzNLX0E4azNaNU43bmZPcTVacWtfUTdJWmZHTFdBQW1DS0RnaA?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Announces $8 Million Registered Direct Offering of Ordinary Shares to Support Clinical Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPOElZVnNacTFhMHNTWFh2S1J1bHJyeHd2NndfNXRkRXEwblFqbjlrUDMtdjJSWExSMHFhWm1lWjEwQWowZk5FQVgzUnlNdGR6WERfVUh1UnhBcHl1OGFOQzZmT1pIc1NmUTJpbmJXLWVDS2o1M2pTeExGb0pRSHpVblpFODc4NkhHaDIxMGVoMnEtdmNrcmRJTTAxTXlSLWVrSk5vNmRyS1RycDNoNWVTR0cySnNsZmUwUnB4ZXRwUWU1NTQycTVETjg3MV9ISFBDRmNrcnNvWFQyb0E4ejZjZkV6QTk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences chairman increases stake to over 36%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPaDR2TmYyNEhSdHFqQkFaZkNZTllUMDdEQmJQVloxaTVVZWEwTzEzX0lZemRTb1dyTF81a2loSEZkRnQ1TVU3WGg1RWFuLWFJQUxkWEdkRzlFRWxKU21udE9ZMkhrb3ZycVp5N1FIX2VDLVlUSU9kc0MtY3ZrYVBtNWt0RW1QTkpRT2N4a0R4U2RiNTYyektxVzE1WW5sTHZHTDlUclVLd2pCWDJjZ0o5N3pjQnA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPQjVBQ1VjV0VTX0JpeTVqeWN5a0tvX09ta1c5RDJlb0hoUlFpZm5RNWZJTTJ4T2pENktPdDA1M1kzMkp4WFFIcFdpOElGaGw5QW1WVHlBNjJhZTBPN19DVmxZLUxaZVA3Wlh2T0RaM2p1djFEUzJuMDkwbFgtcDQ3dm52S01MQVVoY0JTMVhwX0toMWJhZWp5X295VjJWMWNIS0RpMm9yR2pjZURlTkVJblFFX2swU3NYeGxoM2JEMElUVzNUU2dzMlBxS1ZKWXZoTXhaWlduVmhCdGswX2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot (NASDAQ:TLSA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNLXBsSUJmZ0l0M3pkNnJid0Y5LW1XVjM3LWFRSVcta3NTRGZtNFl2Zlk2aEw1bW9GUXFKbXF0dkRSajg5N0tYSVR3TUNqWE1jSzVSY3h3bFRtcnV6Z01MSmxxNUEzbElpZTFqT2hxUU1sREV2X2tGVXAtUDEtaHd3VVlXeXRiZjdRaVJ2dkxyMDU0c2VtVklfSGd5ckkxTWVNWTRYa0JQendUVWR2?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has \u2018So Much Potential\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQQ182a0w4ZjhSaktDTWR2Q09scHNlMUpaWjZVb3RHbmxqYWxRTTJoN2xBTVctMWRrcnBQUkRNZHVBZF85SVlxemdJbjNNQmE5MGNxWDBUajhLdllyTUxhR3pEdlgyWFpHTzgxOXpHQnZSdjBIY18yS2hjNUZlMU8xZzh5TUZLbTM5bDRQRTg3d2tXY01fUjBMSUN3UDNoT2kzWHE4aDFGYjFSZkJnVGZYRmtrQ1dGQ1RIOV9WZkNVUVI?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Leads A Trio Of Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOT1VPM0F2STRYekNlNGVlTkdZSmE4NzBleFBmclU5MWRkeTFFZkRJWVVpaGx2a05HZmpOLW9BOXFEUWV6SFVodUxMb1ZNYzByYl9ndG9hVG0xNWJTUmlydHRWMzhUNjVSMmZTejB1TFJZLTd0dGdvS19RMDAyaldPUWxYeXA?oc=5", "source_name": "Market source", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Com (TLSA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZVWNHc2RBNzIwTGg4NnNkVHFjcFEzaDkybGpoOF9KOFdjTS1iQWpuSGlJYWtkNm5SREZVMzVrZ1ZBbjdMNF9iYVdGYmV2X3U5TzBj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:32:23+00:00", "published_display": "25 Apr 2025 01:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPUHZRLXdZcHJmYVZfT1ZmaDBzY3dPSzQ5UTl2Ul9vYm5WN1d0UDlfR3FCTjFNN0RmUkRWNVpGd1ZRN0xGYWFfQlI1NXBiNW9McmlCZDVpYUVlb2hxdThoQXZQSjZPcjBaYzN4Tk5rVFdZcjlmNm5hcjhpd1RTY0dCRA?oc=5", "source_name": "Market source", "published_at": "2025-03-02T08:00:00+00:00", "published_display": "02 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $TLSA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBhY0MzTnFteXhPTG1BdkJpaGFYdm1VZ2tlcTE1OWNWSEU1TXZZR284RGJIeTQyY2Ftb01OWUdDekcxZ25tQ0F4Z3F2V3lqbkQ2bW1Lc3BqVFZTUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-12-01T17:14:14+00:00", "published_display": "01 Dec 2018 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcG9JN1ktLWpfZnRXRTVLWUJMYWFXb21pdDZsdHlHcFhyTl9IS1BVcjZVQnN2Wm80NmhzbE9GaHlFckRiWU5yN2YzYlB4MEVpTDh2Y0NzSmFXai01U3VINkhRYlpkVHNycjFJeUhScWk3aVJXUjNYUFJVbjVzei1OMW5MXzl6VnlPb3hHZGtEcHZVcTFXX20xbUl4LTJoWHIzYVRLcFFlZzR4NkFMRnZvY2cxdEY3RkhRd2RvLWpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T11:00:33+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This page from TradingView displays the \"Price to book forward\" metric for Tiziana Life Sciences Ltd (NASDAQ: TLSA). The content is primarily a data placeholder, indicating the financial metric for the company, and is surrounded by standard website navigation and footers. The act", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T19:40:23", "published_display": "07 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This article provides financial information for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its price to sales forward metric. It lists the company's stock exchange as Nasdaq and indicates that the market is currently closed with no trades. The content brie", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:12:12", "published_display": "07 Jul 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "The article discusses the enterprise value to revenue forward for Tiziana Life Sciences Ltd, traded on NASDAQ under the ticker TLSA. It presents financial information for the company, accessible through TradingView. The content provides a snapshot of the company's market and fina", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:40:33", "published_display": "05 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tiziana Life Sciences Ltd \u2013 NASDAQ:TLSA", "summary": "This article provides financial data for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its enterprise value to EBIT forward. The content appears to be a stub or an incomplete data presentation page from TradingView, lacking detailed analysis or narrative. It ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:39:25", "published_display": "05 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (DUS:0RP)", "summary": "This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (DUS:0RP), covering income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings report dates, net income figures, dividend policy, and employee ", "url": "https://www.tradingview.com/symbols/DUS-0RP/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T12:09:15", "published_display": "27 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (NASDAQ:TLSA)", "summary": "This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (NASDAQ:TLSA), including its current stock price, historical performance, analyst forecasts, and company financials. It also answers frequently asked questions regarding its stock ticker, market ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:45", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd. Actuals & Estimates (LSX:A3C5SS)", "summary": "This article provides an overview of Tiziana Life Sciences Ltd. (A3C5SS) stock performance, financial actuals, and analyst estimates. It highlights the current stock price, recent declines, market capitalization, and upcoming earnings report. The piece also includes frequently as", "url": "https://www.tradingview.com/symbols/LSX-A3C5SS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:37", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment", "summary": "Tiziana Life Sciences has completed dosing the last patient in its Phase 2 clinical trial for its potential multiple sclerosis treatment, milciclib. The study aims to evaluate milciclib's efficacy and safety in patients with progressive multiple sclerosis. This milestone marks a ", "url": "https://www.moomoo.com/news/post/72034426/tiziana-life-sciences-doses-last-patient-in-phase-2-trial", "source_name": "Moomoo", "published_at": "2026-06-26T07:10:15", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Tiziana Life Sciences Ltd (TLSA) stock. According to one analyst, the 1-year price target is $9.01, with both the maximum and minimum estimates at this value. The article also covers current stock performance, historical highs", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:47", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial", "summary": "Tiziana Life Sciences has dosed the last patient in its Phase 2a clinical trial for intranasal foralumab to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study is anticipated in late Q3 or early Q4 2026, with results planned for presen", "url": "https://ca.finance.yahoo.com/news/tiziana-life-sciences-doses-last-130500188.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-25T17:09:16", "published_display": "25 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tiziana-announces-last-patient-successfully-110000190.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:00:00+00:00", "published_display": "25 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd.", "summary": "Tiziana Life Sciences has announced the successful dosing of the last patient in its Phase 2a INFORM-MS clinical trial for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study, which evaluates intranasal foralumab, a fully human anti-CD3 mono", "url": "https://via.ritzau.dk/pressemeddelelse/15013524/tiziana-life-sciences-ltd?publisherId=90446", "source_name": "Via Ritzau", "published_at": "2026-06-25T11:10:56", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana doses final INFORM-MS patient ahead of late-2026 data", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) has announced the successful dosing of the last patient in its Phase 2a INFORM-MS trial for intranasal foralumab, a treatment for non-active secondary progressive multiple sclerosis. Topline data from this randomized, double-blind, placebo-con", "url": "https://www.stocktitan.net/news/TLSA/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-ge3gmxouug4f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T11:10:56", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) has announced the completion of enrollment for its Phase 2a INFORM-MS trial, with the last patient dosed with intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This randomized, double-blind, placebo-contro", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-1125dc3b129c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T11:10:55", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tiziana Life Sciences Ltd (TLSA), detailing analyst ratings and target prices. Based on one analyst, the stock has a \"Buy\" rating with a target price of USD 8.00, representing a significant upside. The report highlights current marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:10", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tiziana Life Sciences Ltd (TLSA), focusing on its stock performance, indicators, and moving averages. It highlights that critical support and resistance data have not yet been disclosed by the company. The analysis shows an overall 'S", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsa/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:10", "published_display": "18 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (TLSA) insider awarded 15,000 common shares", "summary": "Tiziana Life Sciences Ltd. director Gabriele M. Cerrone was indirectly awarded 15,000 shares of common stock on June 12, 2026, at $1.11 per share through Panetta Partners Limited. This transaction increases his indirect holdings to 44,772,230 shares. The Form 4 filing indicates a", "url": "https://www.stocktitan.net/sec-filings/TLSA/form-4-tiziana-life-sciences-ltd-insider-trading-activity-3f8821dd93b6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:41:04", "published_display": "17 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance", "summary": "Tiziana Life Sciences' Executive Chairman, Gabriele Cerrone, has increased his stake in the company by purchasing 15,000 common shares for $1.11 each, bringing his total holding to 34.89%. This move demonstrates insider confidence as the company advances its intranasal foralumab ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TLSA/pressreleases/2490064/tiziana-life-sciences-chair-boosts-stake-as-foralumab-trials-advance/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T02:10:10", "published_display": "17 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman", "summary": "Tiziana Life Sciences announced that its Executive Chairman and Founder, Gabriele Cerrone, through Panetta Partners Ltd, purchased an additional 15,000 common shares at $1.11 per share. This transaction increases his total holdings to 44,772,230 common shares, representing 34.89%", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman/2365478", "source_name": "The Manila Times", "published_at": "2026-06-15T13:10:10", "published_display": "15 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tiziana-life-sciences-executive-chairman-115515620.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:55:15+00:00", "published_display": "15 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase", "summary": "Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his stake by purchasing 15,000 common shares at $1.11 each, bringing his total holding to 34.89% of the company's issued share capital. The company is developing intranasal foralumab, a fu", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-3d7fd22dad8a.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:09:08", "published_display": "15 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy", "summary": "Tiziana Life Sciences Executive Chairman and founder Gabriele Cerrone increased his stake in the company by purchasing 15,000 common shares at $1.11 each. This transaction, made through Panetta Partners, brings his total holding to 44,772,230 shares, representing 34.89% of the co", "url": "https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-executive-z2vnojl4ymyf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:09:08", "published_display": "15 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana executive chairman increases stake", "summary": "Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his ownership stake in the company through Panetta Partners Ltd. Cerrone purchased 15,000 common shares at $1.11 each, bringing his total holdings to 44.77 million shares, which represents", "url": "https://www.proactiveinvestors.com.au/companies/news/1093905/tiziana-executive-chairman-increases-stake-1093905.html", "source_name": "Proactive financial news", "published_at": "2026-06-15T08:09:57", "published_display": "15 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (Nasdaq:TLSA) - Stock Analysis", "summary": "Tiziana Life Sciences (Nasdaq:TLSA) is a biotechnology company focused on developing therapies for neurodegenerative and lung diseases. The company's lead product candidate, Foralumab, an intranasal anti-CD3 monoclonal antibody, is currently undergoing clinical trials for non-act", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlsa/tiziana-life-sciences", "source_name": "Simply Wall Street", "published_at": "2026-05-31T18:39:14", "published_display": "31 May 2026 18:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York", "summary": "Tiziana Life Sciences announced it will present at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide updates on the company's clinical programs and strategic direction. The presentation will high", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-present-jefferies-110000374.html", "source_name": "Market source", "published_at": "2026-05-31T08:39:47", "published_display": "31 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSA - Tiziana Life Sciences Ltd Stock Price and Quote", "summary": "This page provides a comprehensive overview of Tiziana Life Sciences Ltd (TLSA) stock, including its latest trading data, financial metrics, and recent news. The company is a clinical-stage biotechnology firm focused on therapies for neurodegenerative and lung diseases, with a pi", "url": "https://finviz.com/stock?t=TLSA", "source_name": "Finviz", "published_at": "2026-05-30T18:40:32", "published_display": "30 May 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Tiziana to brief investors on clinical updates at Jefferies event", "summary": "Tiziana Life Sciences (Nasdaq: TLSA) announced it will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide corporate and clinical updates, including advancements for their lead candidate, intranasal foralumab", "url": "https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-to-present-at-the-jefferies-global-healthcare-umf753kly5bh.html", "source_name": "Stock Titan", "published_at": "2026-05-28T11:08:54", "published_display": "28 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC Filing - Form 6-K", "summary": "Tiziana Life Sciences (NASDAQ: TLSA) announced it will present at the Jefferies Healthcare Conference in New York City on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide a corporate presentation highlighting recent clinical and corporate developments, particula", "url": "https://www.stocktitan.net/sec-filings/TLSA/6-k-tiziana-life-sciences-ltd-current-report-foreign-issuer-d8239f192510.html", "source_name": "Stock Titan", "published_at": "2026-05-28T11:08:54", "published_display": "28 May 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial", "summary": "Tiziana Life Sciences has fully enrolled its Phase 2a placebo-controlled clinical trial (INFORM-MS) evaluating intranasal foralumab for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from this novel anti-CD3 monoclonal antibody study is ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tiziana-fully-enrolls-phase-2-150000587.html", "source_name": "Market source", "published_at": "2026-05-22T22:39:57", "published_display": "22 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data \u2013 ICYMI", "summary": "", "url": "https://finance.yahoo.com/m/f9476a36-8271-3245-96bc-18de094f904d/tiziana-life-sciences.html", "source_name": "Proactive", "published_at": "2026-05-22T20:48:00+00:00", "published_display": "22 May 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial", "summary": "", "url": "https://finance.yahoo.com/m/c0f1401c-3ce0-34aa-ba3b-291b4f31034b/tiziana-life-sciences.html", "source_name": "Proactive", "published_at": "2026-05-21T15:44:00+00:00", "published_display": "21 May 2026 15:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPT2E4a05nemNrTHp6X05GMVJ6bzVLWktLTVprOXE0UDlSall3TktBbXdhYnlHaDNZVnlIRTRGSk1Mb1FIclpmSWxtaFlNcFJ5TGNTeG9ZWUdvSEtmRzNLX0E4azNaNU43bmZPcTVacWtfUTdJWmZHTFdBQW1DS0RnaA?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Announces $8 Million Registered Direct Offering of Ordinary Shares to Support Clinical Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPOElZVnNacTFhMHNTWFh2S1J1bHJyeHd2NndfNXRkRXEwblFqbjlrUDMtdjJSWExSMHFhWm1lWjEwQWowZk5FQVgzUnlNdGR6WERfVUh1UnhBcHl1OGFOQzZmT1pIc1NmUTJpbmJXLWVDS2o1M2pTeExGb0pRSHpVblpFODc4NkhHaDIxMGVoMnEtdmNrcmRJTTAxTXlSLWVrSk5vNmRyS1RycDNoNWVTR0cySnNsZmUwUnB4ZXRwUWU1NTQycTVETjg3MV9ISFBDRmNrcnNvWFQyb0E4ejZjZkV6QTk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences chairman increases stake to over 36%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPaDR2TmYyNEhSdHFqQkFaZkNZTllUMDdEQmJQVloxaTVVZWEwTzEzX0lZemRTb1dyTF81a2loSEZkRnQ1TVU3WGg1RWFuLWFJQUxkWEdkRzlFRWxKU21udE9ZMkhrb3ZycVp5N1FIX2VDLVlUSU9kc0MtY3ZrYVBtNWt0RW1QTkpRT2N4a0R4U2RiNTYyektxVzE1WW5sTHZHTDlUclVLd2pCWDJjZ0o5N3pjQnA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPQjVBQ1VjV0VTX0JpeTVqeWN5a0tvX09ta1c5RDJlb0hoUlFpZm5RNWZJTTJ4T2pENktPdDA1M1kzMkp4WFFIcFdpOElGaGw5QW1WVHlBNjJhZTBPN19DVmxZLUxaZVA3Wlh2T0RaM2p1djFEUzJuMDkwbFgtcDQ3dm52S01MQVVoY0JTMVhwX0toMWJhZWp5X295VjJWMWNIS0RpMm9yR2pjZURlTkVJblFFX2swU3NYeGxoM2JEMElUVzNUU2dzMlBxS1ZKWXZoTXhaWlduVmhCdGswX2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot (NASDAQ:TLSA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNLXBsSUJmZ0l0M3pkNnJid0Y5LW1XVjM3LWFRSVcta3NTRGZtNFl2Zlk2aEw1bW9GUXFKbXF0dkRSajg5N0tYSVR3TUNqWE1jSzVSY3h3bFRtcnV6Z01MSmxxNUEzbElpZTFqT2hxUU1sREV2X2tGVXAtUDEtaHd3VVlXeXRiZjdRaVJ2dkxyMDU0c2VtVklfSGd5ckkxTWVNWTRYa0JQendUVWR2?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has \u2018So Much Potential\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQQ182a0w4ZjhSaktDTWR2Q09scHNlMUpaWjZVb3RHbmxqYWxRTTJoN2xBTVctMWRrcnBQUkRNZHVBZF85SVlxemdJbjNNQmE5MGNxWDBUajhLdllyTUxhR3pEdlgyWFpHTzgxOXpHQnZSdjBIY18yS2hjNUZlMU8xZzh5TUZLbTM5bDRQRTg3d2tXY01fUjBMSUN3UDNoT2kzWHE4aDFGYjFSZkJnVGZYRmtrQ1dGQ1RIOV9WZkNVUVI?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Leads A Trio Of Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOT1VPM0F2STRYekNlNGVlTkdZSmE4NzBleFBmclU5MWRkeTFFZkRJWVVpaGx2a05HZmpOLW9BOXFEUWV6SFVodUxMb1ZNYzByYl9ndG9hVG0xNWJTUmlydHRWMzhUNjVSMmZTejB1TFJZLTd0dGdvS19RMDAyaldPUWxYeXA?oc=5", "source_name": "Market source", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences Com (TLSA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZVWNHc2RBNzIwTGg4NnNkVHFjcFEzaDkybGpoOF9KOFdjTS1iQWpuSGlJYWtkNm5SREZVMzVrZ1ZBbjdMNF9iYVdGYmV2X3U5TzBj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:32:23+00:00", "published_display": "25 Apr 2025 01:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPUHZRLXdZcHJmYVZfT1ZmaDBzY3dPSzQ5UTl2Ul9vYm5WN1d0UDlfR3FCTjFNN0RmUkRWNVpGd1ZRN0xGYWFfQlI1NXBiNW9McmlCZDVpYUVlb2hxdThoQXZQSjZPcjBaYzN4Tk5rVFdZcjlmNm5hcjhpd1RTY0dCRA?oc=5", "source_name": "Market source", "published_at": "2025-03-02T08:00:00+00:00", "published_display": "02 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $TLSA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBhY0MzTnFteXhPTG1BdkJpaGFYdm1VZ2tlcTE1OWNWSEU1TXZZR284RGJIeTQyY2Ftb01OWUdDekcxZ25tQ0F4Z3F2V3lqbkQ2bW1Lc3BqVFZTUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-12-01T17:14:14+00:00", "published_display": "01 Dec 2018 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 51, "sentiment_summary": {"positive": 19, "negative": 2, "neutral": 30, "score": 58, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 19, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 1.07, "latest_week": "2026-07-17", "one_week_move": -13.0, "four_week_move": -7.8, "twelve_week_move": -17.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.008351, "market_dynamics_buy_signal": false, "relative_strength": -39.515058, "fair_value_gap": -3.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.3273, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-13.0% over one week, -7.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 2}, {"label": "Proactive", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-13.0% over one week, -7.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake"}], "updated_at": "2026-07-22T11:44:50.171464+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}